Management of Abnormal Uterine Bleeding in Patients with Congestive Heart Failure

Risks and Considerations

Medroxyprogesterone acetate may cause fluid retention, exacerbating heart failure symptoms, and should be used with caution in patients with congestive heart failure, according to the European Society of Cardiology guidelines 1, 2
The European Society of Cardiology guidelines recommend using medroxyprogesterone and other progesterone-only contraceptives with caution in patients with heart failure 1
Monthly injectable forms of medroxyprogesterone acetate are inappropriate for patients with heart failure due to their tendency for fluid retention 1

Assess heart failure severity and current compensation status before initiating treatment for abnormal uterine bleeding, as recommended by the American Heart Association, reflected in Circulation 3, 4
Rule out structural causes of bleeding before attributing bleeding to hormonal or functional causes, as suggested by the American Academy of Family Physicians 5
The European Society of Cardiology recommends the levonorgestrel-releasing intrauterine device as a preferred hormonal option for heart failure patients, as it has minimal systemic absorption and reduces menstrual blood loss by 40-50% 1, 2

Monitor weight and assess for peripheral edema before and during treatment with medroxyprogesterone, and schedule more frequent cardiac follow-up during the initial treatment period, as recommended by the European Society of Cardiology 1, 4
Discontinue medroxyprogesterone if signs of worsening heart failure develop, according to the European Society of Cardiology guidelines 1, 2
Estrogen-containing contraceptives are contraindicated in patients with heart failure due to increased thromboembolism risk, as stated by the American Heart Association, reflected in Circulation 3, 4

Consider hysteroscopic sterilization procedures like Essure for women with chronic heart failure requiring long-term management of abnormal uterine bleeding, if future fertility is not desired, as suggested by the European Society of Cardiology 1
Barrier methods combined with non-hormonal treatments may be preferable for women with severe heart failure, according to the European Society of Cardiology 1